Authorization

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital

SHENZHENA andA SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing of US$10 million Series B Plus strategic financing. This round of financing will be exclusively funded by Shanghai Healthcare Capital ("SHC"), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs.
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
In August 2020, ImmVira and Shanghai Pharma announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors."We warmly welcome SHC to be our strategic investor," saidA Grace Zhou, Chairman and CEO of ImmVira. "This investment further deepens our collaboration in the MVR-T3011 intratumoral program and highlights the commitment from the parties to the program's commercial success. An investment from one of the country's leading integrated pharma and healthcare fund is also a promising validation to the approach of using genetically modified oncolytic virus as an effective remedy to treat cancer."
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
28293031